Literature DB >> 28931227

Enhancement of Zika Infection by Dengue-Specific Antibodies Does Not Alter the Production of Interleukin 6 in FcγRII-Expressing K562 Cells.

Priscila M S Castanha1,2, Eduardo J M Nascimento3,4, Cynthia Braga1,5, Marli T Cordeiro1, Otávio V de Carvalho1, Leila R de Mendonça1, Elisa A N Azevedo1, Rafael F O França1, Rafael Dhalia1, Ernesto T A Marques1,3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28931227      PMCID： PMC5853375          DOI： 10.1093/infdis/jix346

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  10 in total

Review 1.  Dengue Antibody-Dependent Enhancement: Knowns and Unknowns.

Authors:  Scott B Halstead
Journal:  Microbiol Spectr       Date:  2014-12

2.  Zika enhancement: a reality check.

Authors:  Suresh Mahalingam; Mauro M Teixeira; Scott B Halstead
Journal:  Lancet Infect Dis       Date:  2017-06-21       Impact factor: 25.071

3.  Enhancement of Zika Infection by Dengue Virus-Specific Antibody Is Associated With Low Levels of Antiviral Factors.

Authors:  Linda Hueston; Ruben Ramirez; Suresh Mahalingam
Journal:  J Infect Dis       Date:  2017-09-01       Impact factor: 5.226

4.  Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity.

Authors:  Susana V Bardina; Paul Bunduc; Shashank Tripathi; James Duehr; Justin J Frere; Julia A Brown; Raffael Nachbagauer; Gregory A Foster; David Krysztof; Domenico Tortorella; Susan L Stramer; Adolfo García-Sastre; Florian Krammer; Jean K Lim
Journal:  Science       Date:  2017-03-30       Impact factor: 47.728

5.  Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants.

Authors:  S C Kliks; S Nimmanitya; A Nisalak; D S Burke
Journal:  Am J Trop Med Hyg       Date:  1988-03       Impact factor: 2.345

6.  Dengue Virus-Specific Antibodies Enhance Brazilian Zika Virus Infection.

Authors:  Priscila M S Castanha; Eduardo J M Nascimento; Cynthia Braga; Marli T Cordeiro; Otávio V de Carvalho; Leila R de Mendonça; Elisa A N Azevedo; Rafael F O França; Rafael Dhalia; Ernesto T A Marques
Journal:  J Infect Dis       Date:  2017-03-01       Impact factor: 5.226

Review 7.  Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection.

Authors:  Maria G Guzman; Mayling Alvarez; Scott B Halstead
Journal:  Arch Virol       Date:  2013-03-08       Impact factor: 2.574

Review 8.  Biologic Evidence Required for Zika Disease Enhancement by Dengue Antibodies.

Authors:  Scott B Halstead
Journal:  Emerg Infect Dis       Date:  2017-04       Impact factor: 6.883

9.  First experimental in vivo model of enhanced dengue disease severity through maternally acquired heterotypic dengue antibodies.

Authors:  Jowin Kai Wei Ng; Summer Lixin Zhang; Hwee Cheng Tan; Benedict Yan; Julia Maria Martinez; Wei Yu Tan; Jian Hang Lam; Grace Kai Xin Tan; Eng Eong Ooi; Sylvie Alonso
Journal:  PLoS Pathog       Date:  2014-04-03       Impact factor: 6.823

10.  Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus.

Authors:  Wanwisa Dejnirattisai; Piyada Supasa; Wiyada Wongwiwat; Alexander Rouvinski; Giovanna Barba-Spaeth; Thaneeya Duangchinda; Anavaj Sakuntabhai; Van-Mai Cao-Lormeau; Prida Malasit; Felix A Rey; Juthathip Mongkolsapaya; Gavin R Screaton
Journal:  Nat Immunol       Date:  2016-06-23       Impact factor: 25.606
  10 in total
  5 in total

1.  Challenges and solutions in the development of vaccines against emerging and neglected infectious diseases.

Authors:  Joel N Maslow
Journal:  Hum Vaccin Immunother       Date:  2019       Impact factor: 3.452

2.  In-depth characterization of congenital Zika syndrome in immunocompetent mice: Antibody-dependent enhancement and an antiviral peptide therapy.

Authors:  Vidyleison N Camargos; Giselle Foureaux; Daniel C Medeiros; Vivian T da Silveira; Celso M Queiroz-Junior; Ana Luisa B Matosinhos; André F A Figueiredo; Carla D F Sousa; Thaiane P Moreira; Victória F Queiroz; Ana Carolina F Dias; Karina T O Santana; Ingredy Passos; Ana Luíza C V Real; Ludmila C Silva; Flávio A G Mourão; Natália T Wnuk; Milton A P Oliveira; Soraia Macari; Tarcília Silva; Gustavo P Garlet; Joshua A Jackman; Frederico M Soriani; Márcio F D Moraes; Eduardo M A M Mendes; Fabíola M Ribeiro; Guilherme M J Costa; Antônio L Teixeira; Nam-Joon Cho; Antônio C P Oliveira; Mauro M Teixeira; Vivian V Costa; Danielle G Souza
Journal:  EBioMedicine       Date:  2019-05-23       Impact factor: 8.143

3.  Ophthalmological Considerations for COVID-19 Vaccination in Patients with Inflammatory Eye Diseases and Autoimmune Disorders.

Authors:  Charlene Y C Chau; Loraine L W Chow; Siddharth Sridhar; Kendrick C Shih
Journal:  Ophthalmol Ther       Date:  2021-03-06

Review 4.  Control of Acute Arboviral Infection by Natural Killer Cells.

Authors:  Christopher Maucourant; Caroline Petitdemange; Hans Yssel; Vincent Vieillard
Journal:  Viruses       Date:  2019-01-31       Impact factor: 5.048

5.  Letters to the editor on the Zika virus: a bibliometric analysis.

Authors:  Frances A Delwiche
Journal:  J Med Libr Assoc       Date:  2021-04-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.